Ddimer testing

PreclinicalBiologic

AAssistance Publique - Hôpitaux de Paris

Ddimer testing is one of 6 biologic programs targeting Syncope. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SyncopeActive, not recruiting

SyncopePreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Syncope

#DrugCompanyPhaseTrials

Inderal

WWyeth-Lederle Vaccines

Zofran

1 3

Proamatine

Takeda

Preclinical

1 4

Theo-Dur

Pfizer

Preclinical

1 5

Adenocard

Astellas

Preclinical

—6

Ddimer testing

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Syncope1 trial

Prevalence of PE in ED Patients With Isolated Syncope

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT03487237·459 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ddimer testing. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ddimer testing compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ddimer testing. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Ddimer testing

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Syncope1 trial

References

Drug Info

Quick Facts

Related News